Dyne Therapeutics, Inc. (NASDAQ:DYN) on Monday revealed topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
The REC met its primary endpoint, demonstrating a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46% of normal relative to baseline at six months.
